{
    "2018-10-17": [
        [
            {
                "time": "2018-01-02",
                "original_text": "CORRECTING and REPLACING The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AbbVie Inc. (ABBV)",
                "features": {
                    "keywords": [
                        "class action lawsuit",
                        "investors",
                        "AbbVie"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against AbbVie Inc. - ABBV",
                "features": {
                    "keywords": [
                        "shareholder alert",
                        "lawsuit",
                        "AbbVie"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline – ABBV",
                "features": {
                    "keywords": [
                        "shareholder losses",
                        "class action",
                        "AbbVie"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Amgen Launches Humira Biosimilar in Europe",
                "features": {
                    "keywords": [
                        "Amgen",
                        "Humira",
                        "biosimilar",
                        "Europe"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq",
                "features": {
                    "keywords": [
                        "FDA approval",
                        "EyePoint",
                        "Yutiq"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA® (ibrutinib) in Combination with Obinutuzumab (GAZYVA®) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "FDA",
                        "IMBRUVICA",
                        "priority review"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Samsung launches third rival to AbbVie's Humira drug in EU",
                "features": {
                    "keywords": [
                        "Samsung",
                        "Humira",
                        "rival",
                        "EU"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "By Adding Patents, Drugmaker Keeps Cheaper Humira Copies Out of U.S.",
                "features": {
                    "keywords": [
                        "patents",
                        "Humira",
                        "U.S."
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}